Top

Published in:

01-11-2010 | Meeting Report

Advances in cellular therapy: 5th International Symposium on the clinical use of cellular products, 19 and 20 March 2009, Nürnberg, Germany

Authors: Evelyn Ullrich, Jacobus Bosch, Michael Aigner, Simon Völkl, Diana Dudziak, Bernd Spriewald, Gerold Schuler, Reinhard Andreesen, Andreas Mackensen

Published in: Cancer Immunology, Immunotherapy | Issue 11/2010

Excerpt

“Cellular Therapy 2009”: The 5th International Symposium on the Clinical Use of Cellular Products was held in Nuremberg, Germany on 19–20 March 2009. Cellular therapy encompasses a well-established treatment modality exemplified by the curative potential of hematopoietic stem cell transplantation (HSCT). Combinatorial use of cell types such as T cells, natural killer (NK) cells, and antigen-presenting cells (APCs) provides opportunities for a fascinating, emerging concept in the treatment of cancer, autoimmune, and infectious diseases. The 2-day meeting was attended by approximately 350 international guests, and included 40 oral presentations and almost 100 selected poster presentations. The plenary sessions covered hot topics in the field of immune effector cells (T cells, regulatory T cells, NK cells, APC) as well as adoptive T cell transfer, cancer vaccination, and HSCT. Each scientific session included state-of-the-art lectures on pre-clinical and clinical studies. This meeting report will highlight the main issues discussed and summarize the presentations from the plenary sessions. …

Mempel TR, Bauer CA (2009) Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metastasis 26(4):311–327CrossRefPubMed

Mempel TR et al (2006) Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25(1):129–141CrossRefPubMed

Pittet MJ, Mempel TR (2008) Regulation of T-cell migration and effector functions: insights from in vivo imaging studies. Immunol Rev 221:107–129CrossRefPubMed

Willimsky G et al (2008) Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 205(7):1687–1700CrossRefPubMed

Berger C et al (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118(1):294–305CrossRefPubMed

Tykodi SS et al (2004) Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 10(23):7799–7811CrossRefPubMed

Takahashi Y et al (2008) Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 118(3):1099–1109PubMed

zur Hausen H (1996) Papillomavirus infections—a major cause of human cancers. Biochim Biophys Acta 1288(2):F55–F78PubMed

Kenter GG et al (2008) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14(1):169–177CrossRefPubMed

10.

Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8(5):351–360CrossRefPubMed

11.

Zwaveling S et al (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169(1):350–358PubMed

12.

Vambutas A et al (2005) Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23(45):5271–5280CrossRefPubMed

13.

Welters MJ et al (2008) Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14(1):178–187CrossRefPubMed

14.

Sozzani S et al (2007) Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 28(9):385–392CrossRefPubMed

15.

Riboldi E et al (2005) Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol 175(5):2788–2792PubMed

16.

Copier J et al (2007) Cell based cancer vaccines: regulatory and commercial development. Vaccine 25(Suppl 2):B35–B46CrossRefPubMed

17.

Copier J et al (2006) Biomarkers for the development of cancer vaccines: current status. Mol Diagn Ther 10(6):337–343PubMed

18.

Green DS et al (2007) Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 156(2):337–345CrossRefPubMed

19.

Green DS et al (2008) Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 159(3):606–614CrossRefPubMed

20.

Bonehill A et al (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16(6):1170–1180CrossRefPubMed

21.

Bonehill A et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15(10):3366–3375CrossRefPubMed

22.

Walzer T et al (2007) Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci USA 104(9):3384–3389CrossRefPubMed

23.

Chiossone L et al (2009) Maturation of mouse NK cells is a 4-stage developmental program. Blood 113(22):5488–5496CrossRefPubMed

24.

Davis DM, Sowinski S (2008) Membrane nanotubes: dynamic long-distance connections between animal cells. Nat Rev Mol Cell Biol 9(6):431–436CrossRefPubMed

25.

Sowinski S et al (2008) Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol 10(2):211–219CrossRefPubMed

26.

Andoniou CE et al (2008) Killers and beyond: NK-cell-mediated control of immune responses. Eur J Immunol 38(11):2938–2942CrossRefPubMed

27.

Ruggeri L et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097–2100CrossRefPubMed

28.

Ruggeri L et al (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110(1):433–440CrossRefPubMed

29.

Ferrara JL et al (2009) Graft-versus-host disease. Lancet 373(9674):1550–1561CrossRefPubMed

30.

Blatt NB et al (2002) Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility. J Clin Invest 110(8):1123–1132PubMed

31.

Zakrzewski JL et al (2006) Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med 12(9):1039–1047CrossRefPubMed

32.

Zuniga-Pflucker JC (2004) T-cell development made simple. Nat Rev Immunol 4(1):67–72CrossRefPubMed

33.

Zakrzewski JL et al (2008) Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 26(4):453–461CrossRefPubMed

34.

Edinger M et al (2003) CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9(9):1144–1150CrossRefPubMed

35.

Kohrt HE et al (2009) TLI and ATG conditioning with low risk of graft-versus-host disease retains anti-tumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 114(5):1099–1109CrossRefPubMed

36.

Spellman S et al (2008) Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant 14(9 Suppl):37–44CrossRefPubMed

37.

Petersdorf EW et al (2007) MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med 4(1):e8CrossRefPubMed

38.

Petersdorf EW, Hansen JA (2008) New advances in hematopoietic cell transplantation. Curr Opin Hematol 15(6):549–554CrossRefPubMed

39.

Miwa H et al (1992) Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia 6(5):405–409PubMed

40.

Candoni A et al (2009) Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 82(1):61–68CrossRefPubMed

41.

Collison LW et al (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169):566–569CrossRefPubMed

42.

Chatenoud L et al (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91(1):123–127CrossRefPubMed

43.

Keymeulen B et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352(25):2598–2608CrossRefPubMed

44.

Belghith M et al (2003) TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9(9):1202–1208CrossRefPubMed

45.

Floess S et al (2007) Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 5(2):e38CrossRefPubMed

46.

Mantel PY et al (2006) Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 176(6):3593–3602PubMed

47.

Tone Y et al (2008) Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 9(2):194–202CrossRefPubMed

48.

Polansky JK et al (2008) DNA methylation controls Foxp3 gene expression. Eur J Immunol 38(6):1654–1663CrossRefPubMed

49.

Baron U et al (2007) DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 37(9):2378–2389CrossRefPubMed

50.

Wieczorek G et al (2009) Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 69(2):599–608CrossRefPubMed

51.

Golshayan D et al (2007) In vitro-expanded donor alloantigen-specific CD4+ CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 109(2):827–835CrossRefPubMed

52.

Jiang S et al (2006) Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: potential reagents to promote donor-specific transplantation tolerance. Transplantation 82(12):1738–1743CrossRefPubMed

53.

Tsang JY et al (2008) Conferring indirect allospecificity on CD4+ CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 118(11):3619–3628CrossRefPubMed

54.

Hoffmann P et al (2004) Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 104(3):895–903CrossRefPubMed

55.

Hoffmann P et al (2006) Only the CD45RA+ subpopulation of CD4+ CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 108(13):4260–4267CrossRefPubMed

56.

Hoffmann P et al (2009) Loss of FOXP3 expression in natural human CD4+ CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 39(4):1088–1097CrossRefPubMed

Title: Advances in cellular therapy: 5th International Symposium on the clinical use of cellular products, 19 and 20 March 2009, Nürnberg, Germany
Authors: Evelyn Ullrich
Jacobus Bosch
Michael Aigner
Simon Völkl
Diana Dudziak
Bernd Spriewald
Gerold Schuler
Reinhard Andreesen
Andreas Mackensen
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0779-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2010

Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells

Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles

Leukemic cell products down-regulate human dendritic cell differentiation

A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth

Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice

Differential gene expression in acute lymphoblastic leukemia cells surviving allogeneic transplant

Keynote webinar | Spotlight on antibody–drug conjugates in cancer